Market Risers: Rainbow Rare Earths Ltd, Union Jack Oil PLC, AstraZeneca plc & EVRAZ plc

Rainbow Rare Earths

Shares in Rainbow Rare Earths Ltd ticker code: LON:RBW has gained 9.17% or 0.33 points during today’s session so far. Market buyers are a positive bunch during the trading session. Range high for the period so far is 4.15 while the low for the session was 3.63. The number of shares traded by this point in time totalled 1,945,376 while the average shares exchanged is 753,388. A 52 week high for the stock is 20.8 amounting to 17.2 points in difference on the previous days close and a 52 week low being 1.55 making a difference of 2.05 points. Rainbow Rare Earths Ltd now has a 20 simple moving average of 2.44 and a 50 day moving average now at 2.16. The current market cap is £8.02m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Rainbow Rare Earths Ltd being recorded at Thursday, May 23, 2019 at 11:57:04 AM GMT with the stock price trading at 3.93 GBX.


Shares in Union Jack Oil PLC with company EPIC: LON:UJO has climbed 5.89% or 0.01 points in today’s trading session so far. Buyers seem confident during the session. Range high for the period so far is 0.14 while the low for the session was 0.13. The volume total for shares traded up to this point was 88,377,934 with the daily average at 103,020,243. A 52 week share price high is 0.17 around 0.04 points difference from the previous days close and the 52 week low at 0.08 a difference of some 0.05 points. Union Jack Oil PLC has a 20 day moving average of 0.11 with a 50 day SMA of 0.1. This puts the market capitalisation now at £14.86m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Union Jack Oil PLC being recorded at Thursday, May 23, 2019 at 11:47:17 AM GMT with the stock price trading at 0.14 GBX.


Shares of AstraZeneca plc with ticker code: LON:AZN has stepped up 1.55% or 92 points throughout today’s trading session so far. Buyers seem confident throughout the trading session. The period high was 6064 and hitting a low of 5982. The amount of shares exchanged has so far reached 658,267 whilst the daily average number of shares exchanged is just 2,465,389. A 52 week high for the stock is 6540 which is 602 points in difference on the previous days close and a 52 week low being 5110 which is a difference of 828 points. AstraZeneca plc now has a 20 moving average of 5856.5 and the 50 day SMA of 6090.87. The market cap now stands at £79,099.08m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Thursday, May 23, 2019 at 11:59:58 AM GMT with the stock price trading at 6030 GBX.


The trading price for EVRAZ plc EPIC code: LON:EVR has increased 1.46% or 8.6 points in today’s trading session so far. Investors have remained optimistic throughout the session. Range high for the period has seen 600.4 and a low of 584. The volume total for shares traded up to this point was 1,650,021 with the average number of shares traded daily being 3,216,956. A 52 week share price high is 674 around 84.6 points difference from the previous days close and the 52 week low at 435.5 is a variance of 153.9 points. EVRAZ plc has a 20 day moving average of 609.14 and now the 50 day moving average at 627.66. The market capitalisation is now £8,673.70m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for EVRAZ plc being recorded at Thursday, May 23, 2019 at 12:02:02 PM GMT with the stock price trading at 598 GBX.

Share on:
Find more news, interviews, share price & company profile here for:
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials.
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care.
Union Jack Oil Plc (LON:UJO, OTCQB: UJOGF) continues to move forward with its growth strategy, particularly with its expansion into the United States.
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer.
Union Jack Oil plc updates on the Moccasin 1-13 well in Oklahoma, confirming it as a commercial oil discovery with promising production rates and potential revenue growth.
UJO is rapidly progressing with the installation of permanent production facilities, a move that underlines the strength of its US expansion strategy.

Search

Search